Juliana Machado-Rugolo

Dr. Juliana Machado-Rugolo

Pharmaceutical Sciences Graduate Course, Universidade de Sorocaba, Sorocaba, São Paulo, Brazil
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
MMMilena Soriano Marcolino
Milena Soriano Marcolino
MPMagda C. Pires
Magda C. Pires
LRLucas Emanuel F. Ramos
Lucas Emanuel F. Ramos
RSRafael T. Silva
Rafael T. Silva
LOLuana M. Oliveira
Luana M. Oliveira
CPCarisi Anne Polanczyk
Carisi Anne Polanczyk
The majority of available scores to assess mortality risk of coronavirus disease 19 (COVID-19) patients in the emergency department have high risk of bias. Therefore, our aim was to develop and validate a score at hospital admission for predicting in-hospital mortality in COVID-19 patients, and to compare this score with other existing ones. Consecutive patients (≥18 years) with confirmed COVID-19 admitted to the participating hospitals were included. Logistic regression analysis was performed to develop a prediction model for in-hospital mortality, based on the 3978 patients admitted between March-July, 2020. The model was validated in the 1054 patients admitted during August-September, as well as in an external cohort of 474 Spanish patients. Median (25th-75th percentile) age of the model-derivation cohort was 60 (48-72) years, and in-hospital mortality was 20.3%. The validation cohorts had similar age distribution and in-hospital mortality. Seven significant variables were included in the risk score: age, blood urea nitrogen, number of comorbidities, C-reactive protein, SpO2/FiO2 ratio, platelet count and heart rate. The model had high discriminatory value (AUROC 0.844, 95% CI 0.829 to 0.859), which was confirmed in the Brazilian (0.859 [95% CI 0.833 to 0.885]) and Spanish (0.894 [95% CI 0.870 to 0.919]) validation cohorts, and displayed better discrimination ability than other existing scores. It is implemented in a freely available online risk calculator (https://abc2sph.com/). We designed and validated an easy-to-use rapid scoring system based on characteristics of COVID-19 patients commonly available at hospital presentation, for early stratification for in-hospital mortality risk of patients with COVID-19.

5 January 2024 in BMC Geriatrics
Verified
Journal Article
Open access
PDF file
MBMaria Aparecida Camargos Bicalho
Maria Aparecida Camargos Bicalho
MAMárlon Juliano Romero Aliberti
Márlon Juliano Romero Aliberti
PDPolianna Delfino-Pereira
Polianna Delfino-Pereira
VCVictor Schulthais Chagas
Victor Schulthais Chagas
PRPatryk Marques da Silva Rosa
Patryk Marques da Silva Rosa
MMMilena Soriano Marcolino
Milena Soriano Marcolino
Background: Although dementia has emerged as an important risk factor for severe SARS-CoV-2 infection, results on COVID-19-related complications and mortality are not consistent. We examined the clinical presentations and outcomes of COVID-19 in a multicentre cohort of in-hospital patients, comparing those with and without dementia. Methods: This retrospective observational study comprises COVID-19 laboratory-confirmed patients aged ≥ 60 years admitted to 38 hospitals from 19 cities in Brazil. Data were obtained from electronic hospital records. A propensity score analysis was used to match patients with and without dementia (up to 3:1) according to age, sex, comorbidities, year, and hospital of admission. Our primary outcome was in-hospital mortality. We also assessed admission to the intensive care unit (ICU), invasive mechanical ventilation (IMV), kidney replacement therapy (KRT), sepsis, nosocomial infection, and thromboembolic events. Results: Among 1,556 patients included in the study, 405 (4.5%) had a diagnosis of dementia and 1,151 were matched controls. When compared to matched controls, patients with dementia had a lower frequency of dyspnoea, cough, myalgia, headache, ageusia, and anosmia; and higher frequency of fever and delirium. They also had a lower frequency of ICU admission (32.7% vs. 47.1%, p < 0.001) and shorter ICU length of stay (7 vs. 9 days, p < 0.026), and a lower frequency of sepsis (17% vs. 24%, p = 0.005), KRT (6.4% vs. 13%, p < 0.001), and IVM (4.6% vs. 9.8%, p = 0.002). There were no differences in hospital mortality between groups. Conclusion: Clinical manifestations of COVID-19 differ between older inpatients with and without dementia. We observed that dementia alone could not explain the higher short-term mortality following severe COVID-19. Therefore, clinicians should consider other risk factors such as acute morbidity severity and baseline frailty when evaluating the prognosis of older adults with dementia hospitalised with COVID-19.

2 September 2022 in BMC Medicine
Verified
Journal Article
Open access
PDF file
FFFlávio de Azevedo Figueiredo
Flávio de Azevedo Figueiredo
LRLucas Emanuel Ferreira Ramos
Lucas Emanuel Ferreira Ramos
RSRafael Tavares Silva
Rafael Tavares Silva
DPDaniela Ponce
Daniela Ponce
RCRafael Lima Rodrigues Carvalho
Rafael Lima Rodrigues Carvalho
MMMilena Soriano Marcolino
Milena Soriano Marcolino
Background: Acute kidney injury (AKI) is frequently associated with COVID-19, and the need for kidney replacement therapy (KRT) is considered an indicator of disease severity. This study aimed to develop a prognostic score for predicting the need for KRT in hospitalised COVID-19 patients, and to assess the incidence of AKI and KRT requirement. Methods: This study is part of a multicentre cohort, the Brazilian COVID-19 Registry. A total of 5212 adult COVID-19 patients were included between March/2020 and September/2020. Variable selection was performed using generalised additive models (GAM), and least absolute shrinkage and selection operator (LASSO) regression was used for score derivation. Accuracy was assessed using the area under the receiver operating characteristic curve (AUC-ROC). Results: The median age of the model-derivation cohort was 59 (IQR 47–70) years, 54.5% were men, 34.3% required ICU admission, 20.9% evolved with AKI, 9.3% required KRT, and 15.1% died during hospitalisation. The temporal validation cohort had similar age, sex, ICU admission, AKI, required KRT distribution and in-hospital mortality. The geographic validation cohort had similar age and sex; however, this cohort had higher rates of ICU admission, AKI, need for KRT and in-hospital mortality. Four predictors of the need for KRT were identified using GAM: need for mechanical ventilation, male sex, higher creatinine at hospital presentation and diabetes. The MMCD score had excellent discrimination in derivation (AUROC 0.929, 95% CI 0.918–0.939) and validation (temporal AUROC 0.927, 95% CI 0.911–0.941; geographic AUROC 0.819, 95% CI 0.792–0.845) cohorts and good overall performance (Brier score: 0.057, 0.056 and 0.122, respectively). The score is implemented in a freely available online risk calculator (https://www.mmcdscore.com/). Conclusions: The use of the MMCD score to predict the need for KRT may assist healthcare workers in identifying hospitalised COVID-19 patients who may require more intensive monitoring, and can be useful for resource allocation.

29 December 2022 in Data
Verified
Journal Article
Open access
PDF file
NRNaila Rocha
Naila Rocha
ABAbner Macola Pacheco Barbosa
Abner Macola Pacheco Barbosa
YSYaron Oliveira Schnr
Yaron Oliveira Schnr
Juliana Machado-RugoloJuliana Machado-Rugolo
Juliana Machado-Rugolo
LALuis Gustavo Modelli de Andrade
Luis Gustavo Modelli de Andrade
LSLiciana Vaz de Arruda Silveira
Liciana Vaz de Arruda Silveira
Studies that use medical records are often impeded due to the information presented in narrative fields. However, recent studies have used artificial intelligence to extract and process secondary health data from electronic medical records. The aim of this study was to develop a neural network that uses data from unstructured medical records to capture information regarding symptoms, diagnoses, medications, conditions, exams, and treatment. Data from 30,000 medical records of patients hospitalized in the Clinical Hospital of the Botucatu Medical School (HCFMB), São Paulo, Brazil, were obtained, creating a corpus with 1200 clinical texts. A natural language algorithm for text extraction and convolutional neural networks for pattern recognition were used to evaluate the model with goodness-of-fit indices. The results showed good accuracy, considering the complexity of the model, with an F-score of 63.9% and a precision of 72.7%. The patient condition class reached a precision of 90.3% and the medication class reached 87.5%. The proposed neural network will facilitate the detection of relationships between diseases and symptoms and prevalence and incidence, in addition to detecting the identification of clinical conditions, disease evolution, and the effects of prescribed medications.

1 March 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
BPBruno Barbosa Miranda de Paiva
Bruno Barbosa Miranda de Paiva
PPPolianna Delfino Pereira
Polianna Delfino Pereira
CAClaudio Moises Valiense de Andrade
Claudio Moises Valiense de Andrade
VGVirginia Mara Reis Gomes
Virginia Mara Reis Gomes
MSMaira Viana Rego Souza-Silva
Maira Viana Rego Souza-Silva
MMMilena Soriano Marcolino
Milena Soriano Marcolino
The majority of early prediction scores and methods to predict COVID-19 mortality are bound by methodological flaws and technological limitations (e.g., the use of a single prediction model). Our aim is to provide a thorough comparative study that tackles those methodological issues, considering multiple techniques to build mortality prediction models, including modern machine learning (neural) algorithms and traditional statistical techniques, as well as meta-learning (ensemble) approaches. This study used a dataset from a multicenter cohort of 10,897 adult Brazilian COVID-19 patients, admitted from March/2020 to November/2021, including patients [median age 60 (interquartile range 48–71), 46% women]. We also proposed new original population-based meta-features that have not been devised in the literature. Stacking has shown to achieve the best results reported in the literature for the death prediction task, improving over previous state-of-the-art by more than 46% in Recall for predicting death, with AUROC 0.826 and MacroF1 of 65.4%. The newly proposed meta-features were highly discriminative of death, but fell short in producing large improvements in final prediction performance, demonstrating that we are possibly on the limits of the prediction capabilities that can be achieved with the current set of ML techniques and (meta-)features. Finally, we investigated how the trained models perform on different hospitals, showing that there are indeed large differences in classifier performance between different hospitals, further making the case that errors are produced by factors that cannot be modeled with the current predictors.

1 January 2014 in Applied Immunohistochemistry & Molecular Morphology
Verified
Journal Article
Closed access
BEBruna Estrozi
Bruna Estrozi
Juliana Machado-RugoloJuliana Machado-Rugolo
Juliana Machado-Rugolo
RRRubens Rodriguez
Rubens Rodriguez
CBCarlos E. Bacchi
Carlos E. Bacchi
Cutaneous melanoma in young patients is rare with increasing incidence. It is not clear whether the etiology and clinical outcome are similar to cutaneous melanoma in the elderly. Mutations in BRAF gene in patients with cutaneous melanoma, in general, range in frequency from 20% to 80%; however, the status and clinical significance of BRAF mutations in the young population have not been evaluated. We investigated 132 cases of primary cutaneous melanoma in patients aged between 18 and 30 years with emphasis on clinical characteristics, pathologic features, and molecular evaluation of mutation in the BRAF gene (BRAF V600E). It was predominantly seen in female individuals (61.4%), trunk was the most common site of involvement (40.4%), and superficially spreading melanoma was the predominant histologic type (79.5%). Mutation in BRAF V600E was analyzed successfully in 93 cases using an RT-PCR. The BRAF V600E mutation was identified in 38.7% (36/93) and was associated with vertical growth phase (P=0.01) and mild inflammatory infiltrate (P=0.02). No case of melanoma with regression phenomenon presented with BRAF V600E mutation (P<0.05). There was no significant association between BRAF V600E mutation and sex, histologic type, the Clark level, the Breslow index, solar elastosis, angiolymphatic and perineural invasion, satellitosis, and coexisting nevus. As in melanomas in older patients, these results probably indicate that BRAF mutation may not be the only key factor in melanoma tumorigenesis, and that there should be multiple alternative genetic pathways related to melanoma.